来源：新浪证券-红岸工作室 2月25日，爱迪特涨9.03%，成交额6.80亿元，换手率12.81%，总市值80.78亿元。 异动分析 专精特新+3D打印+牙科医疗+医疗器械概念+人民币贬值受益 1、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部国家级专 精特新小巨人企业名单。 2、根据公司官网显示，公司生产的CPD-100 3D打印机可进行30纳米高精度打印。 3、爱迪特(秦皇岛)科技股份有限公司主营业务为口腔修复材料的研发、生产和销售；口腔数字化设备 的设计和销售。公司主要产品为口腔修复材料、口腔数字化设备、口腔正畸产品、口腔预防产品。 4、爱迪特(秦皇岛)科技股份有限公司主营业务为口腔修复材料的研发、生产和销售；口腔数字化设备 的设计和销售。公司主要产品为口腔修复材料、口腔数字化设备、口腔正畸产品、口腔预防产品。 5、根据2024年年报，公司海外营收占比为61.85%，受益于人民币贬值。 ( ...

2月24日，爱迪特涨9.39%，成交额6.12亿元，换手率12.21%，总市值74.08亿元。 来源：新浪证券-红岸工作室 异动分析 专精特新+3D打印+牙科医疗+医疗器械概念+人民币贬值受益 区间今日近3日近5日近10日近20日主力净流入-2412.25万-3992.23万161.16万611.87万2700.13万 1、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部国家级专 精特新小巨人企业名单。 2、根据公司官网显示，公司生产的CPD-100 3D打印机可进行30纳米高精度打印。 3、爱迪特(秦皇岛)科技股份有限公司主营业务为口腔修复材料的研发、生产和销售；口腔数字化设备 的设计和销售。公司主要产品为口腔修复材料、口腔数字化设备、口腔正畸产品、口腔预防产品。 4、爱迪特(秦皇岛)科技股份有限公司主营业务为口腔修复材料的研发、生产和销售；口腔数字化设备 的设计和销售。公司主要产品为口腔修复材 ...

Core Viewpoint - Spring Medical has experienced a decline in stock price and trading volume, with a notable drop in recent trading days, indicating potential investor concerns about the company's performance and market position [1]. Group 1: Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is based in Tongzhou District, Beijing, and specializes in the research, production, and sales of implantable orthopedic medical devices [1]. - The company's main products include joint prosthetics (hip, knee, shoulder, elbow) and a full range of spinal implant products [1]. - The revenue composition of the company is predominantly from medical device products at 99.89%, with other sources contributing 0.11% [1]. Group 2: Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, which is a significant increase of 213.21% [2]. - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3]. Group 3: Market Activity - As of February 12, 2023, Spring Medical's stock price was 22.40 yuan per share, with a market capitalization of 8.592 billion yuan [1]. - The stock has seen a year-to-date decline of 1.20%, a 5-day drop of 3.16%, an 18.13% decrease over the past 20 days, and a 12.98% decline over the last 60 days [1]. - The company has experienced a net outflow of 1.0456 million yuan in principal funds, with large orders accounting for 3.27% of purchases and 8.11% of sales [1].

Core Viewpoint - Aidi Tech (Qinhuangdao) Co., Ltd. has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the dental medical and medical device sectors [1][2]. Company Overview - Aidi Tech specializes in the research, production, and sales of dental restoration materials and digital dental equipment, with main products including dental restoration materials, digital dental devices, orthodontic products, and preventive dental products [2][8]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [2]. Financial Performance - For the period from January to September 2025, Aidi Tech achieved a revenue of 747 million yuan, representing a year-on-year growth of 16.44%, and a net profit attributable to shareholders of 142 million yuan, reflecting a growth of 27.40% [8]. - The company's overseas revenue accounted for 61.85% of total revenue, benefiting from the depreciation of the RMB [3]. Market Position and Trading Activity - The stock price of Aidi Tech increased by 4.63% on February 11, with a trading volume of 251 million yuan and a turnover rate of 6.40%, leading to a total market capitalization of 5.88 billion yuan [1]. - The stock has seen a net inflow of 26.89 million yuan from major investors, indicating a positive trend in investor interest [5][6]. Technical Analysis - The average trading cost of Aidi Tech's shares is 49.66 yuan, with the current stock price fluctuating between resistance at 58.50 yuan and support at 50.20 yuan, suggesting potential for short-term trading strategies [7].

Group 1 - The core viewpoint of the news is that Beijia Clean has experienced a significant stock price increase of 36.20% year-to-date, with recent trading activity showing a slight decline in stock price and net outflow of funds [2][1]. - As of February 10, Beijia Clean's stock price was reported at 40.97 yuan per share, with a total market capitalization of 4.115 billion yuan [1]. - The company has a diverse revenue structure, with 35.13% from other products, 33.23% from toothbrushes, 24.81% from wet wipes, and 6.83% from probiotics [2]. Group 2 - Beijia Clean's revenue for the first nine months of 2025 reached 1.119 billion yuan, reflecting a year-on-year growth of 18.75%, while the net profit attributable to shareholders was 77.0674 million yuan, up 84.58% year-on-year [2]. - The company has distributed a total of 115 million yuan in dividends since its A-share listing, with 46.145 million yuan distributed over the past three years [3]. - The company is categorized under the beauty and personal care industry, specifically in the personal care and hygiene products sector, and is involved in the research, production, and sales of oral hygiene and disposable sanitary products [2].

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design and inspection phase for customized porous tantalum dental implants [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998. The company went public on December 30, 2021, and primarily engages in the research, production, and sales of implantable orthopedic medical devices [7]. - The main products include joint prosthetics and spinal implant products, covering four major human joints: hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [8]. Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [8]. Industry Position - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, and is involved in various concept sectors including dental medical, robotics, and innovative enterprises [8]. Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 2.9585 million shares, and new entrants such as China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A [9].

Core Viewpoint - Spring Medical experienced a decline of 1.24% on February 4, with a trading volume of 49.12 million yuan and a total market capitalization of 8.834 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is currently in the design and inspection phase for a customized porous tantalum dental implant product [2] - Spring Medical has obtained registration certificates for hip and knee surgical robots and medical image processing software, indicating its investment in smart medical technology [2][3] Industry Position - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the national evaluation of small and medium-sized enterprises, highlighting its strong innovation capabilities and market share [3] - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [5][8] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan in the last three years [8] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Central European Economic Selection Mixed A, both of which are new shareholders [9]

Core Viewpoint - Aidi Tech (Qinhuangdao) Co., Ltd. is experiencing growth in its dental medical and medical device sectors, benefiting from the depreciation of the RMB and its status as a "specialized, refined, distinctive, and innovative" enterprise [2][3]. Company Overview - Aidi Tech specializes in the research, production, and sales of dental restoration materials and digital dental equipment, with main products including dental restoration materials, digital dental devices, orthodontic products, and preventive dental products [2][2]. - The company was established on March 15, 2007, and is located in Qinhuangdao, Hebei Province. It went public on June 26, 2024 [8]. - The revenue composition of Aidi Tech includes 73.74% from dental restoration materials, 19.80% from digital dental equipment, and 6.46% from other products and services [8]. Financial Performance - For the period from January to September 2025, Aidi Tech achieved a revenue of 747 million yuan, representing a year-on-year growth of 16.44%, and a net profit attributable to shareholders of 142 million yuan, with a year-on-year increase of 27.40% [8]. - The company has distributed a total of 49.48 million yuan in dividends since its A-share listing [9]. Market Position and Recognition - Aidi Tech has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position, innovation capabilities, and high market share [2]. - The company benefits from a significant overseas revenue share of 61.85%, aided by the depreciation of the RMB [3]. Technical Analysis - The average trading cost of Aidi Tech's shares is 48.94 yuan, with recent trends indicating a rapid outflow of shares. The current stock price is near a support level of 50.80 yuan, which is critical for potential rebounds [7].

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of Spring Medical, indicating a recent stock price increase and overall market activity [1][2]. - As of February 2, Spring Medical's stock price rose by 2.00% to 23.97 CNY per share, with a total market capitalization of 9.194 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 5.73%, but has seen declines of 9.92% over the last five trading days and 11.42% over the last 60 days [1]. Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products being joint prosthetics and spinal implants [1]. - The company reported a revenue of 756 million CNY for the period from January to September 2025, reflecting a year-on-year growth of 48.75%, and a net profit of 192 million CNY, which is a 213.21% increase compared to the previous year [2]. - The company has distributed a total of 440 million CNY in dividends since its A-share listing, with 390 million CNY distributed over the last three years [3]. Group 3 - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables, with relevant sectors including dental medical, medical devices, and orthopedic materials [2]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Fund, both of which are new entrants among the top ten circulating shareholders [3].

Core Viewpoint - Spring Medical has shown a significant increase in stock price and trading volume, indicating positive market sentiment towards the company and its growth potential in the orthopedic medical device sector [1]. Company Overview - Spring Medical is a leading domestic manufacturer of orthopedic medical devices, focusing on the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2][5]. - The company’s main products include joint prosthetics for the hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [2][5]. - Spring Medical is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [3]. Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a substantial increase of 213.21% [8]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [8]. Market Position and Shareholder Information - As of September 30, 2025, the number of shareholders in Spring Medical increased by 4.12% to 6,164, while the average number of circulating shares per person decreased by 3.95% [8]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Fund, indicating growing interest from institutional investors [9]. Technical Analysis - The average trading cost of the stock is 23.50 yuan, with recent buying activity observed, although the strength of this accumulation is not strong [6]. - The stock price is approaching a resistance level of 26.41 yuan, suggesting potential for a price correction if this level is not surpassed [6].